Trials / Completed
CompletedNCT02385760
CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris
A Multi-centre, Double-blind, Randomized, Parallel Group, Placebo Controlled Efficacy and Safety Study of Oral CTX-4430 for the Treatment of Moderate to Severe Facial Acne Vulgaris
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 124 (actual)
- Sponsor
- Celtaxsys, Inc. · Academic / Other
- Sex
- All
- Age
- 16 Years – 44 Years
- Healthy volunteers
- Not accepted
Summary
A multi-centre, double-blind, randomized, parallel group, placebo controlled efficacy and safety study of oral CTX-4430 for the treatment of moderate to severe facial acne vulgaris.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CTX-4430 | |
| DRUG | Placebo |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2016-05-01
- Completion
- 2016-08-01
- First posted
- 2015-03-11
- Last updated
- 2016-08-02
Locations
10 sites across 2 countries: Australia, New Zealand
Source: ClinicalTrials.gov record NCT02385760. Inclusion in this directory is not an endorsement.